Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1
Advanced Gastric Cancer
DRUG: Camrelizumab|DRUG: Apatinib Mesylate|DRUG: nab-paclitaxel|DRUG: S1
major pathological response, major pathological response（MPR）, 4 months
pathological complete response, pathological complete response (pCR), 4 months|Objective response rate, Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST, 4 months|R0 resection rate, The surgical procedure was total or subtotal gastrectomy with 3 weeks after total neoadjuvant therapy., 4 months
To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1